Shares of clinical-stage company Prothena (NASDAQ:PRTA) are soaring today as Biogen’s (NASDAQ:BIIB) promising results for lecanemab put the spotlight on Alzheimer’s names.
Prothena has expertise in protein dysregulation and a pipeline focused on neurodegenerative and rare peripheral amyloid diseases including Alzheimer’s and Parkinson’s disease.
Is PRTA a Good Stock to Buy?
Overall the Street has a Strong Buy consensus rating on PRTA stock alongside an average price target of $69.60 which indicates a 27.36% potential upside.
That’s after a nearly 85% rise in Prothena stock over the past five days.
Read full Disclosure
